Compare Citius Pharmaceuticals Inc (CTXR) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Johnson Controls International PLC trades at $154.59 (market cap $93.74B). The key difference: Johnson Controls International PLC is far larger — about 4684.7× Citius Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | JCI | |
|---|---|---|
Market Cap | $20.01M | $93.74B |
Sector | Health | Industrials |
52-Week High | $1.82 | $154.76 |
52-Week Low | $0.48 | $103.52 |
Enterprise Value | $16.23M | $102.58B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Johnson Controls International (JCI) trades at $154.06, up 2.23% on the day, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust Q3 2026 results with organic sales growth of 10% and raised its full-year guidance, driven by demand for data-center thermal management systems. Valuation ratios are elevated, with a P/E of 43.59 and P/S of 3.82, reflecting growth expectations. The stock is near its pivot point of $154, with immediate resistance at $155.
The outlook for JCI is positive, supported by strong operational momentum and strategic positioning in energy-efficient building solutions. Key opportunities include expanding AI-related cooling demand and consistent earnings outperformance. Risks involve high valuation multiples, increasing debt-to-asset ratios, and potential macroeconomic pressures on construction markets. Analyst consensus remains strongly bullish with a $168.25 price target, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
